Clinical Trial Update: Venetoclax After TKI to Target Persisting Stem Cells in CML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating venetoclax after tyrosine kinase inhibitors to eradicate persisting stem cells in chronic myeloid leukemia; currently listed a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Venclexta (venetoclax)

Snippet

Sponsor: Thomas Ernst, PD Dr. med. | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING